R.F. NASYROVA¹, D.V. IVASHCHENKO¹, K.K. YAKHIN², N.G. NEZNANOV¹

¹St.-Petersburg V.M. Bekhterev Research Psychoneurological Institute, 3 Bekhterev Str., Saint-Petersburg, Russian Federation, 192019

²Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

Nasyrova R.F. ― D. Med. Sc., Head of the Department of Personalized Psychiatry and Neurology, tel. (812) 670-02-37, e-mail: [email protected]

Ivashchenko D.V. ― resident, tel. (812) 670-02-37, e-mail: [email protected]

Yakhin K.K. ― D. Med. Sc., Professor, Head of the Department of Psychiatry and Narcology, tel. (843) 238-13-88, e-mail: [email protected]

Neznanov N.G. ― D. Med. Sc., Professor, Director, tel. (812) 670-02-37, e-mail: [email protected]

The article discusses the possibility of implementing personalized approaches to the treatment of mental disorders that require the use of antipsychotics. It analyzes the international experience of implementing the results of pharmacogenetic studies in the clinical practice of psychiatric services and the factors limiting the implementation of pharmacogenetic testing in the Russian Federation. The necessity to develop programs of decision-making support is substantiated, which would be available for psychiatrists at their workplaces.

Key words: personalized medicine, pharmacogenetics, antipsychotics, metabolic disturbances.

REFERENCES

1. Kennedy J.L., Altar C.A., Taylor D.L. et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int. Clin. Psychopharmacol, 2014, vol. 29, no. 2, pp. 63-76.
2. Ichikawa J., Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiatry Clin. Neurosci, 1999, no. 249, suppl 4, pp. 90-98.
3. Biologicheskie metody terapii psikhicheskikh rasstroystv, pod red. S.N. Mosolova [Biological methods of therapy of mental disorders. Ed. by S.N. Mosolov]. Moscow: Dokazatel’naya meditsina ― klinicheskoy praktike, 2012. 1078 p.
4. Lieberman J.A., Stroup T.S., McEvoy J.P. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med, 2005, vol. 353, no. 12, pp. 1209-1223.
5. Üçok A., Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry, 2008, vol. 7, no. 1, pp. 58-62.
6. Leucht S., Tardy M., Komossa K. et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet, 2012, vol. 379, no. 2, pp. 2063-2071.
7. Nasyrova R.F., Ivanov M.V., Neznanov N.G. Vvedenie v psikhofarmakogenetiku [Introduction to psychopharmacogenetics]. Saint Petersburg: Izdatel’skiy tsentr SPb NIPNI im. V.M. Bekhtereva, 2015. 272 p.
8. Winner J.G., Dechairo B., Yale J. Combinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical Utility. J. Biol. Med, 2015, vol. 88, no. 4, pp. 375-382.